Publications by authors named "O Alcazar"

Article Synopsis
  • - The research focuses on developing small-molecule inhibitors (SMIs) targeting the CD40-CD40L interaction to improve islet transplantation outcomes and prevent type 1 diabetes (T1D) in mice.
  • - Promising SMIs DRI-C21041 and DRI-C21095 demonstrated the ability to prolong islet allograft survival and functionality while reducing T1D incidence in NOD mice during trials.
  • - These findings suggest that CD40L-targeting SMIs could provide a safer and more effective alternative to traditional antibody treatments, offering better control and ease of administration for transplant recipients and autoimmune disease prevention.
View Article and Find Full Text PDF

Vascular diseases, including peripheral arterial disease (PAD), pulmonary arterial hypertension, and atherosclerosis, significantly impact global health due to their intricate relationship with vascular remodeling. This process, characterized by structural alterations in resistance vessels, is a hallmark of heightened vascular resistance seen in these disorders. The influence of environmental estrogenic endocrine disruptors (EEDs) on the vasculature suggests a potential exacerbation of these alterations.

View Article and Find Full Text PDF

Background: Type 1 diabetes (T1D) is a devastating autoimmune disease, and its rising prevalence in the United States and around the world presents a critical problem in public health. While some treatment options exist for patients already diagnosed, individuals considered at risk for developing T1D and who are still in the early stages of their disease pathogenesis without symptoms have no options for any preventive intervention. This is because of the uncertainty in determining their risk level and in predicting with high confidence who will progress, or not, to clinical diagnosis.

View Article and Find Full Text PDF

Background: Biomarkers of early pathogenesis of type 1 diabetes (T1D) are crucial to enable effective prevention measures in at-risk populations before significant damage occurs to their insulin producing beta-cell mass. We recently introduced the concept of integrated parallel multi-omics and employed a novel data augmentation approach which identified promising candidate biomarkers from a small cohort of high-risk T1D subjects. We now validate selected biomarkers to generate a potential composite signature of T1D risk.

View Article and Find Full Text PDF